# EDGAR Filing Document

**Accession Number:** 0001175680
**File Stem:** 0001104659-23-022094
**Filing Date:** 2023-2
**Character Count:** 6974
**Document Hash:** b165a255b14e6b0424afb8ec163f565c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-022094.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001104659-23-022094

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230213

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Arman Arvin Cyrus
- **CENTRAL INDEX KEY:** 0001939191

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-49908
- **FILM NUMBER:** 23633131

**MAIL ADDRESS:**
- **STREET 1:** 1111 MAIN STREET
- **STREET 2:** SUITE 660
- **CITY:** VANCOUVER
- **STATE:** WA
- **ZIP:** 98660
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CytoDyn Inc.
- **CENTRAL INDEX KEY:** 0001175680
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 753056237
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0531

**BUSINESS ADDRESS:**
- **STREET 1:** 1111 MAIN STREET, SUITE 660
- **CITY:** VANCOUVER
- **STATE:** WA
- **ZIP:** 98660
- **BUSINESS PHONE:** 360-980-8524

**MAIL ADDRESS:**
- **STREET 1:** 1111 MAIN STREET, SUITE 660
- **CITY:** VANCOUVER
- **STATE:** WA
- **ZIP:** 98660

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTODYN INC
- **DATE OF NAME CHANGE:** 20031114

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** REXRAY CORP
- **DATE OF NAME CHANGE:** 20020617

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Arman Arvin Cyrus<br><sub>(Last) (First) (Middle)</sub><br>1111 MAIN STREET, SUITE 660<br><sub>(Street)</sub><br>VANCOUVER, WA 98660<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-13 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>CytoDyn Inc. [ CYDY ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-02-13 |  | A |  | 434782<sup>(1)(2)</sup> | A | <sup>(2)</sup> | 1081334<sup>(2)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Warrants (right to buy) | $0.50 | 2023-02-13 |  | A |  | 434782<sup>(1)(2)</sup> |  | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 434782<sup>(1)(2)</sup> | <sup>(2)</sup> | 434782<sup>(2)</sup> | D |  |

---

### Footnotes:

(1) The reported securities are included within Units purchased by the reporting person in a private placement directly with the Company. The terms are identical to a concurrent offering being conducted through a placement agent (the "Offering"). Each "Unit" consists of one share of common stock and one warrant to purchase one share of common stock.

(2) The number of Units and the corresponding numbers of shares and warrants have been calculated based on a purchase price of $0.23 per Unit, which was equal to 90% of the intraday volume weighted average price of the common stock on January 12, 2023, the date of the first closing in the Offering. The number of Units and corresponding numbers of shares and warrants purchased in the Offering will increase if 90% of the intraday volume weighted average price of a share of common stock on the final closing date in the Offering is lower than $0.23. The revised numbers will be calculated by dividing $100,000 by such lower price.

(3) The warrants will become exercisable in full on the final closing date of the Offering. The warrants will expire five years after the exercise date.

**Signature:** /s/ Antonio Migliarese, Attorney-In-Fact  
**Date:** 2023-02-14

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**